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CBD: A Resource for Patients
RYAN HARNED
LARNER COLLEGE OF MEDICINE, UNIVERSITY OF VERMONT
FAMILY MEDICINE CLERKSHIP, AUGUST -SEPTEMBER 2019

Problem
In my first 10 days working at Hinesburg Family Practice:
◦ 11 patients mentioned unprompted that they were using CBD products
◦ 2 patients asked if they ought to try using it

Cannabidiol (CBD) products are promoted as a cure-all supplement for many ailments
Many people use it, and it is widely available both in stores and online
Hemp is replacing corn cultivation in many areas of Vermont

Little objective information on CBD and other hemp products is available to patients

Public Health Considerations
How many patients are using it? What types of patients are most likely to use it?
What are the risks? What should patients know? What medication interactions exist?
Are a significant number of patients putting themselves at risk by using a widely promoted yet
largely unregulated product?

Community Perspectives
Dr. JIM ULAGER

Family Physician

“A major challenge with both CBD and marijuana legalization is
that because it remains federally illegal, it really limits the ability to
do research on their effects on patients.”

“Some patients with chronic illnesses who have failed other
treatments have reported that CBD really helps them. The benefits
may outweigh the risks in these adults, but I’m much more
cautious about CBD use in patients under 25 years old. We don’t
know what effects it can have on people whose brains, especially
the frontal cortex, are still developing.”

LAUREN BODE, PharmD

Clinical Pharmacist

“I find my mind somewhat split on CBD in general. The level of
evidence is in no way good enough for me to recommend it over
other evidence-based therapies. But the reality is that
conventional therapies for depression, anxiety, and pain fail a lot
of people. I have become more accepting of CBD as a potential
adjunct in that case.”
“That said, I do also recommend caution to patients. Use a
reputable supplier, ask to see testing information, and start at a
low dose and increase slowly. It is a chemical substance so it
should be treated with the same caution as any other medication.”
“Confounding factors in practice, of course, are potential variations
in the CBD product used given that the majority of these products
are not tightly regulated (with the exception of Epidiolex).”
Regarding potential drug interactions between topical CBD
(creams, lotions, etc.) and medications: “I would not expect an
interaction with topical CBD as absorption is thought to be fairly
limited.”

Methodology
Develop an educational handout for patients, incorporating:
◦ Current body of research on what CBD does/doesn’t work for
◦ Laws regulating production, sale, advertising
◦ Safety concerns
◦ Purity, content
◦ Medication interactions

Considerations:
◦ Written in language that is accessible to patients
◦ Avoid appearing to promote CBD

Response
Patients: Overwhelmingly positive
◦ Admitted they didn’t know how best to research CBD on their own
◦ Pleased that a doctors’ office could provide an objective resource they could trust

Providers: Positive
◦ Glad to have a handout they can provide
◦ Served as a good reference for them as well

Limitations & Effectiveness Assessment
Many unknowns exist:
◦ We still don’t know how many patients use CBD, and who those patients are
◦ It was difficult to identify which patients should be provided the handout ◦ Are certain types of patients are more likely to use it - younger age? Patients with musculoskeletal pain?

◦ Research hasn’t revealed which patients should be targeted for CBD education
◦ Who is at high risk for medication interactions?
◦ Are any patients at risk for potential disease complications?

The body of CBD research is constantly changing, therefore the handout will require periodic updating

Future Recommendations
Proposal for future research: Incorporate two brief surveys
Initial brief survey when providing the handouts
◦ For the patient to fill out: assess whether they use CBD already, how likely they are to start using CBD
products, whether they feel they have access to quality research/informational materials
◦ For the provider to fill out: Note what major medical conditions the patient has, what medications they
take, basic demographic data (age, gender, etc., without providing identifiers)

Second survey at follow-up visit
◦ Inquire whether the patient chose to use CBD if they hadn’t already, whether current users changed
their habits after receiving the handout, and whether they thought the handout affected their use

Research goals:
◦ Identify patients most likely to use CBD – target those cohorts for education
◦ Assess whether handout affected they decision to use CBD – want to avoid unintentional promotion
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